Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70016 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Cheng-Jie Ke und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Oxcarbazepine, Models, Biological, Anticonvulsants, Carbamazepine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, China, Joint Funds for the Innovation of Science and Technology, Fujian Province, China, Young and Middle-aged Backbone Personnel Training Project of Fujian Province Health and Family Planning Commission, China.
Abstract (Originalsprache)
Aims
Oxcarbazepine (OXC) has been approved as monotherapy or adjunctive therapy for paediatric partial seizures. There are few reports on the pharmacokinetics (PK) of OXC in paediatric patients with renal impairment (RI), especially dosage studies of RI, which are rarely conducted on paediatric patients. This study aimed to predict the PK of OXC in children with RI and to provide recommendations for dose adjustment in this population.
Methods
Physiologically based pharmacokinetic (PBPK) models of the active metabolites of OXC were developed and verified, and their disposition was simulated in populations with or without RI.
Results
A fold error value of less than 2 was observed based on the simulated results from PBPK models for single‐ and multi‐dose administration. Based on the predictions for paediatric patients with moderate, severe, and end‐stage RI, the dose should be adjusted to 50, 40 and 25% of the normal dose, respectively, in children aged 2–5 years; and 50, 30 and 20%, respectively, in children aged 6–17 years.
Conclusions
The developed PBPK model is a valuable tool for predicting the OXC dosage in paediatric patients with RI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- The School of Pharmacy, Fujian Medical University, Fuzhou, China.
ORCID-Profile: Cheng-Jie Ke, Si-Ting Liu, Yu-Die Qian, Cui-Hong Lin, Wei-Wei Lin
Förderung
- Natural Science Foundation of Fujian Province, China
- Joint Funds for the Innovation of Science and Technology, Fujian Province, China
- Young and Middle-aged Backbone Personnel Training Project of Fujian Province Health and Family Planning Commission, China
- Young and Middle-aged Teachers Education Research Project of Fujian Province, China
Zitieren
APA
Ke, C. J., Liu, S. T., Qian, Y. D., You, X., Lin, R. F., Lin, C. H., Huang, P. F., & Lin, W. W. (2025). Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70016
Vancouver
Ke CJ, Liu ST, Qian YD, You X, Lin RF, Lin CH, et al. Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70016
BibTeX
@article{Ke2025,
author = {Ke, Cheng-Jie and Liu, Si-Ting and Qian, Yu-Die and You, Xiang and Lin, Rong-Fang and Lin, Cui-Hong and Huang, Pin-Fang and Lin, Wei-Wei},
title = {Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70016}
}
EUVIMED